#SFHS2610716AFrance Adds Negaban Temocillin Injections to Hospital Add-On Reimbursement List
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This order adds two Negaban temocillin injectable products, in 1 g and 2 g strengths, to the list of medicines that hospitals can bill separately from standard hospital service payments. The added reimbursement only applies when the medicine is used for specified infections in adults and children, including complicated urinary tract infections, lower respiratory tract infections, bacteraemia, and wound infections. Hospitals, pharmacists, and payers should apply the separate reimbursement only for these approved uses and in line with official guidance on proper antibacterial use.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Adds Negaban 2 g injectable temocillin to the hospital add-on reimbursement list
- Adds Negaban 1 g injectable temocillin to the same list
- Limits separate reimbursement to specified infections in adults and children, with proper antibacterial-use guidance to be considered
Obligations
What this law requires
Hospitals may bill NEGABAN 2 g (temocillin), powder for injectable/perfusion solution, UCD code 3400892955056, separately from hospital service payments only when used for the approved reimbursable indications listed in the annex.
Hospitals may bill NEGABAN 1 g (temocillin), powder for injectable/perfusion solution, UCD code 3400892954974, separately from hospital service payments only when used for the approved reimbursable indications listed in the annex.
Separate reimbursement by health insurance for the listed NEGABAN products must be limited to treatment of adults and children with complicated urinary tract infections, including pyelonephritis.
Separate reimbursement by health insurance for the listed NEGABAN products must be limited to treatment of adults and children with lower respiratory tract infections, bacteraemia, or wound infections.
When using the listed NEGABAN temocillin products, healthcare providers must take account of official recommendations on the appropriate use of antibacterials.